SEC Tracker
Get the app

Olema Pharmaceuticals OLMA

Olema Pharmaceuticals reports Q3 2026 results

Olema Pharmaceuticals (OLMA) filed an 8-K with the SEC on Nov 10, 2026, 7:05 am ET. Source: the filing on SEC EDGAR.

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. Ended Q3 2026 with $413.8 million in cash, cash equivalents, and marketable securities
  2. Net loss for Q3 2026 was $73.6 million, up from $42.2 million in Q3 2025
  3. Appointed Jason O'Byrne as Chief Financial Officer

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Olema Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.